Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial

Main Article Content

KA Papp
M Lebwohl
AB Gottlieb
M Sebastian
R Langley
Y Okubo
M Wang
C Cioffi
F Staelens
K Reich


Plaque Psoriasis, Bimekizumab, Nail Psoriasis, Scalp Psoriasis, Palmoplantar Psoriasis


Abstract not available.


1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Reich K. AAD 2020 Oral Presentation

6. Merola JF. Dermatol Ther 2018;e12589.

Most read articles by the same author(s)

1 2 3 4 > >>